ACADIA Pharmaceuticals
ACADIA Pharmaceuticals
ACAD
NASDAQ
17.99
USD
7.27%
About
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases.
Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis.
Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.4M |
| Three Month Average Volume | 37.9M |
| High Low | |
| Fifty-Two Week High | 32.59 USD |
| Fifty-Two Week Low | 14.55 USD |
| Fifty-Two Week High Date | 22 Dec 2023 |
| Fifty-Two Week Low Date | 10 Jun 2024 |
| Price and Volume | |
| Current Price | 16.58 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -16.39% |
| Thirteen Week Relative Price Change | 2.59% |
| Twenty-Six Week Relative Price Change | -37.20% |
| Fifty-Two Week Relative Price Change | -51.03% |
| Year-to-Date Relative Price Change | -55.28% |
| Price Change | |
| One Day Price Change | 1.59% |
| Thirteen Week Price Change | 9.80% |
| Twenty-Six Week Price Change | -30.95% |
| Five Day Price Change | 4.02% |
| Fifty-Two Week Price Change | -38.64% |
| Year-to-Date Price Change | -47.05% |
| Month-to-Date Price Change | -12.83% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.62226 USD |
| Book Value Per Share (Most Recent Quarter) | 3.1154 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.2245 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 2.46508 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 0.20714 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 4.43439 USD |
| Revenue Per Share (Trailing Twelve Months) | 5.38215 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.37411 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | 0.18131 USD |
| Normalized (Last Fiscal Year) | -0.37411 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.37411 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | 0.18316 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.37411 USD |
| Including Extraordinary Items (Trailing Twelve Months) | 0.18131 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.66544 USD |
| Cash Per Share (Most Recent Quarter) | 3.02039 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.33997 USD |
| Cash Flow Per Share (Trailing Twelve Months) | 0.25398 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 0.48638 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -22 |
| Cash Flow Revenue (Trailing Twelve Months) | 9 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | 5.14% |
| Pretax Margin (Last Fiscal Year) | -7.03% |
| Pretax Margin (5 Year) | -37.76% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 94.27% |
| Gross Margin (Trailing Twelve Months) | 91.72% |
| Gross Margin (5 Year) | 95.62% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -10.10% |
| Operating Margin (Trailing Twelve Months) | 2.56% |
| Operating Margin (5 Year) | -39.88% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -8.44% |
| Net Profit Margin (Trailing Twelve Months) | 3.43% |
| Net Profit Margin (5 Year) | -38.35% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -4.67% |
| Tangible Book Value (5 Year) | -5.07% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 46.44% |
| Revenue Growth (3 Year) | 26.55% |
| Revenue Change (Trailing Twelve Months) | 61.65% |
| Revenue Per Share Growth | 20.19% |
| Revenue Growth (5 Year) | 18.03% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 79.52% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 2,876.74% |
| EPS Change (Trailing Twelve Months) | 126.51% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 8 |
| Price to Tangible Book (Most Recent Quarter) | 7 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 34 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -500,942,000 |
| Net Debt (Last Fiscal Year) | -438,865,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 4 |
| Price to Sales (Trailing Twelve Months) | 3 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | 91 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | 89 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 90 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 90 |
| PE Including Extraordinary Items (Trailing Twelve Months) | 91 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 6 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | 0.00% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 |
| Quick Ratio (Most Recent Quarter) | 2 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | 54 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -23,348,000 |
| Free Cash Flow (Trailing Twelve Months) | 80.5M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -9.17% |
| Return on Assets (Trailing Twelve Months) | 3.93% |
| Return on Assets (5 Year) | -27.50% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -14.73% |
| Return on Equity (Trailing Twelve Months) | 6.70% |
| Return on Equity (5 Year) | -35.33% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -12.81% |
| Return on Investment (Trailing Twelve Months) | 5.93% |
| Return on Investment (5 Year) | -32.73% |